These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
3. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF; Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392 [TBL] [Abstract][Full Text] [Related]
4. Resistance testing debate: does it make the grade? Simmons P Res Initiat Treat Action; 1999 Oct; 5(4):9-12. PubMed ID: 11366943 [TBL] [Abstract][Full Text] [Related]
5. HIV resistance testing: more questions than answers. Mirken B AIDS Treat News; 1997 Nov; (No 283):3-5. PubMed ID: 11364909 [TBL] [Abstract][Full Text] [Related]
6. HIV-1 drug resistance assays in clinical management. Martinez-Picado J; D'Aquila R AIDS Clin Care; 1998 Nov; 10(11):81-5, 87-8. PubMed ID: 11365861 [TBL] [Abstract][Full Text] [Related]
7. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015 [TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Torti C; Quiros-Roldan E; Regazzi M; De Luca A; Mazzotta F; Antinori A; Ladisa N; Micheli V; Orani A; Patroni A; Villani P; Lo Caputo S; Moretti F; Di Giambenedetto S; Castelnuovo F; Maggi P; Tinelli C; Carosi G; Clin Infect Dis; 2005 Jun; 40(12):1828-36. PubMed ID: 15909273 [TBL] [Abstract][Full Text] [Related]
9. Genotypic resistance tests for the clinical management of patients with primary HIV infection. Narciso P; Lazzarin A Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588 [TBL] [Abstract][Full Text] [Related]
10. Genotypic resistance tests for the management of the HIV-infected pregnant woman. Bassetti D; Cargnel A Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589 [TBL] [Abstract][Full Text] [Related]
11. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count. Jaafar A; Massip P; Sandres-Sauné K; Souyris C; Pasquier C; Aquilina C; Izopet J J Med Virol; 2004 Sep; 74(1):8-15. PubMed ID: 15258962 [TBL] [Abstract][Full Text] [Related]
12. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Loutfy MR; Raboud JM; Walmsley SL; Saskin R; Montaner JS; Hogg RS; Thompson CA; Harrigan PR Antivir Ther; 2004 Aug; 9(4):595-602. PubMed ID: 15456091 [TBL] [Abstract][Full Text] [Related]
13. Your next nightmare: 28% of new HIV cases may be drug-resistant. AIDS Alert; 1999 Dec; 14(12):133-7. PubMed ID: 11366987 [TBL] [Abstract][Full Text] [Related]
14. Will drug resistance testing prove reliable enough to enhance HIV treatments? Murphy MJ Fac Notes (New Orleans La); 1998; 10(6):1-3. PubMed ID: 11366139 [TBL] [Abstract][Full Text] [Related]
15. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure. Montroni M; Monforte AD Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591 [TBL] [Abstract][Full Text] [Related]
16. Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy. Morand-Joubert L; Charpentier C; Poizat G; Chêne G; Dam E; Raguin G; Taburet AM; Girard PM; Hance AJ; Clavel F Antivir Ther; 2006; 11(2):143-54. PubMed ID: 16640095 [TBL] [Abstract][Full Text] [Related]
17. Salvage therapy: still more intuition than data. Gilden D GMHC Treat Issues; 1999 Jan; 13(1):6-12. PubMed ID: 11366112 [TBL] [Abstract][Full Text] [Related]
18. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain. Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R; J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444 [TBL] [Abstract][Full Text] [Related]